Humedix Co., Ltd. (KOSDAQ:200670)
South Korea · Delayed Price · Currency is KRW 69,300
+1,000 (1.46%)
Sep 16, 2025, 3:30 PM KST
Humedix Revenue
In the year 2021, Humedix had annual revenue of 110.99B KRW with 12.70% growth. Humedix had revenue of 30.37B in the quarter ending December 31, 2021, a decrease of -13.10%.
Revenue
110.99B
Revenue Growth
+12.70%
P/S Ratio
6.44
Revenue / Employee
447.55M
Employees
248
Market Cap
715.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 110.99B | 12.51B | 12.70% |
| Dec 31, 2020 | 98.48B | 19.86B | 25.26% |
| Dec 31, 2019 | 78.62B | 13.79B | 21.27% |
| Dec 31, 2018 | 64.83B | 10.10B | 18.46% |
| Dec 31, 2017 | 54.73B | 7.59B | 16.11% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |